Close Menu
August 22, 2019
Sponsored by
BC Platforms

Biobanks and the Rise of Precision Medicine: Lessons from the Estonian Biobank


Vice Director, Institute of Genomics, University of Tartu,
Head of the Estonian Biobank Science Center

This webinar discusses how the Estonian Biobank, a cohort of more than 165,000 participants, is addressing industry challenges with data management and collaboration in the transition to precision medicine.

The explosion of big data, together with rapidly developing technology, holds untapped potential for drug discovery and personalized healthcare studies. Accordingly, biobanks are emerging as an essential tool for discovery and clinical development, with their extensive datasets originating from diverse profiles of individuals and populations. However, the full power of this data is yet to be unlocked, due to both industry and academia grappling with challenges in managing, harmonizing, and integrating data and resources.

The following webinar discusses the ways to address and potentially solve such industry challenges, with insights from the Vice-Director of the Estonian Genome Center, Tonu Esko. The Estonian Biobank is one of the world’s leading resources for developing precision medicine applications, with its forward-looking laws, longitudinal digital health repositories, and availability of biological samples. Their work aims to promote the development of human genetics research, collecting information on health issues and genetics of the Estonian population, and implement genomic data in medical practice, with the aim to improve population health.

The discussion highlights the Estonian Biobank’s experience supporting precision medicine and operating as a data partner in BC Platforms’ global network, a secure environment for data reservoirs to display their data collections, while maintaining ownership and security, for pharmaceutical researchers who seek diverse patient cohorts for clinical research and drug development projects.

Sponsored by

Nature News reports on how meeting cancellations and related costs are affecting scientific societies.

In a new ruling, Canada's Supreme Court upheld the country's genetic non-discrimination law, the Canadian Press reports.

COVID-19 vaccine developers aim to avoid a complication that has affected efforts to develop vaccines for other diseases, the Wall Street Journal reports.

In PLOS this week: analysis of insertions throughout Shigella genomes, antigen production in malaria parasites, and more.

Sponsored by

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Sponsored by

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Sponsored by

“If we build it, they will come” is a familiar refrain that echoes in life science entrepreneurial circles. Too frequently startups believe that if a technology is built it will sell.

Sponsored by

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.